![](https://jstindt.com/wp-content/uploads/2024/01/france-one-of-the-largest-eu-markets-for-pharma.webp)
Pricing and Reimbursement France – Securing Early Reimbursement Through the Early Access Programs
France’s Reimbursed Early Access Programs (EAPs) allow for reimbursement of new medicines before traditional reimbursement and even before Marketing Authorization.
![](https://jstindt.com/wp-content/uploads/2023/05/Bio-Pharma.jpg)
HAS Early Access Program: Positive Trends After Two Years
The Haute Autorité de Santé (HAS) has recently shared a two-year summary of its Early Access program. The highlights include:
![Germany Pharma Market Figures](https://jstindt.com/wp-content/uploads/2024/01/germany-pharma-market-figures.jpg)
Pricing and Reimbursement in Germany – Possibility of price increases for legacy products
In an effort to control rising cost Germany introduced both a price freeze preventing price increases on legacy products effective